These findings will be further evaluated in our clinical trial (NCT04634058) about the combination of anti-PD-L1 and anti-CTLA-4 in treating ICC patients, which is already in progress. The gene discussed is CTLA4; the disease is intrahepatic cholangiocarcinoma.